Physician profile
John Stephen Dodd
NPI 1003104670
$4,544.36
in general payments reported to CMS, 2019-2025
22 companies · $747 in 2025
The $747 reported for 2025 was more than what 83% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,088 · 2022: $1,560 · 2023: $712 · 2024: $437 · 2025: $747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,896.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,895.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $751.16 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $579.53 | 2021-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $399.98 | 2021-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $390.44 | 2021-2025 | Camzyos, Eliquis |
| Amgen INC. | $343.39 | 2021-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $316.79 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $312.21 | 2021-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $256.30 | 2021-2025 | Farxiga, Andexxa, Lokelma |
| Medtronic, INC. | $226.78 | 2021-2025 | Reveal Linq, Corevalve Evolut R, Linq II |
| Boston Scientific Corporation | $212.99 | 2022-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Daiichi Sankyo INC. | $165.09 | 2021-2024 | Injectafer |
| Amarin Pharma, INC. | $135.96 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $101.39 | 2023-2025 | Amvuttra |
| Esperion Therapeutics, INC. | $90.89 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $57.60 | 2023-2024 | Inpefa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $52.41 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $35.96 | 2021-2022 | |
| Nuwellis, INC. | $29.57 | 2021-2022 | |
| Scpharmaceuticals INC. | $23.26 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.23 | 2025 | Lifevest |
| Bridgebio Pharma, INC. | $20.95 | 2025 | Attruby |
| Vital Connect, INC | $20.48 | 2023 | Vitalpatch Rtm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dodd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.